This month we’re talking about  advances in prostate cancer  immunotherapy. The interviews  are informative and lucid—  quite an achievement as cancer  immunotherapy is quite complex.  One important takeaway is that  Provenge (sipuleucel-T) is much  more effective when the tumor burden  is low. In my experience, this treatment  is often offered when metastatic  spread is too extensive for optimal  effectiveness. Perhaps cost is one  reason. Provenge (sipuleucel-T)  is about $90,000. Many patients  face 20% copays, which mean outof-  pocket fees of $18,000. Charles Myers, MD.

View January's publication